{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:46:57Z","timestamp":1791316017585,"version":"4.3.1"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["HHSO100201600031C"],"award-info":[{"award-number":["HHSO100201600031C"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biotechnology Journal"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>During the COVID\u201019 pandemic, long development timelines typically associated with vaccines were challenged. The urgent need for a vaccine provided a strong driver to reevaluate existing vaccine development approaches. Innovative approaches to regulatory approval were realized, including the use of platform\u2010based technology. In collaboration with the International AIDS Vaccine Initiative, Inc. (IAVI), Merck &amp; Co., Inc., Rahway, NJ, USA rapidly advanced an investigational SARS\u2010CoV\u20102 vaccine based on the recombinant vesicular stomatitis virus (rVSV) platform used for the Ebola vaccine ERVEBO (rVSV\u2206G\u2010ZEBOV\u2010GP). An rVSV\u2206G\u2010SARS\u2010CoV\u20102 vaccine candidate was generated using the SARS\u2010CoV\u20102 spike protein to replace the VSV G protein. The purification process development for this vaccine candidate was detailed in this paper. Areas were highlighted where the ERVEBO platform process was successfully adopted and where additional measures were needed for the SARS\u2010CoV\u20102 vaccine candidate. These included: (i) endonuclease addition directly into the bioreactor prior to harvest, (ii) inclusion of a core\u2010shell chromatography step for improved purification, and (iii) incorporation of a terminal, sterile filtration step to eliminate the need for aseptic, closed processing. High infectious virus titers were achieved in Phase 3 clinical drug substance (&gt;10<jats:sup>8<\/jats:sup> PFU\u00a0mL<jats:sup>\u22121<\/jats:sup>), and process consistency was demonstrated across four large scale batches that were completed in 6 months from clone selection.<\/jats:p>","DOI":"10.1002\/biot.202300041","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T03:39:35Z","timestamp":1695872375000},"source":"Crossref","is-referenced-by-count":4,"title":["Adaptation of an rVSV Ebola vaccine purification process for rapid development of a viral vaccine candidate for SARS\u2010CoV\u20102"],"prefix":"10.1002","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7503-6820","authenticated-orcid":false,"given":"Laura E.","family":"Kuczynski","sequence":"first","affiliation":[{"name":"Vaccine Process Research &amp; Development MRL Merck &amp; Co., Inc.  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Shallow","sequence":"additional","affiliation":[{"name":"Vaccine Process Research &amp; Development MRL Merck &amp; Co., Inc.  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Watson","sequence":"additional","affiliation":[{"name":"Vaccine Process Research &amp; Development MRL Merck &amp; Co., Inc.  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Homsy","sequence":"additional","affiliation":[{"name":"Vaccine Process Research &amp; Development MRL Merck &amp; Co., Inc.  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Svab","sequence":"additional","affiliation":[{"name":"Vaccine Process Research &amp; Development MRL Merck &amp; Co., Inc.  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Gruber","sequence":"additional","affiliation":[{"name":"Analytical Research &amp; Development MRL Merck &amp; Co., Inc  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Rustandi","sequence":"additional","affiliation":[{"name":"Analytical Research &amp; Development MRL Merck &amp; Co., Inc  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfang","family":"Hu","sequence":"additional","affiliation":[{"name":"Center of Mathematical Sciences MMD Merck &amp; Co., Inc.  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Winters","sequence":"additional","affiliation":[{"name":"Vaccine Process Research &amp; Development MRL Merck &amp; Co., Inc.  West Point Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"e_1_2_10_2_1","volume-title":"Covid\u201019 vaccine tracker and landscape","author":"World Health Organization","year":"2022"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401\u2010020\u20100485\u20104"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2021.04.061"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586\u2010020\u201003626\u20101"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7013e3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201096879\u20103"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040385"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2015.03.032"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.059"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2039"},{"key":"e_1_2_10_12_1","volume-title":"Replicating Vaccines. Birkh\u00e4user Advances in Infectious Diseases","author":"Dormitzer P. R.","year":"2011"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2014.05.007"},{"key":"e_1_2_10_14_1","unstructured":"Ervebo (rVSV\u0394G\u2010Zebov\u2010GP) ebola vaccine. (2022).Precision vaccinations.https:\/\/www.precisionvaccinations.com\/vaccines\/ervebo\u2010ebola\u2010vaccine"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104203"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(16)32621\u20106"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104138"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.045"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28088"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2019.100009"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.btre.2023.e00782"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010021\u201086688\u2010z"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/biot.202200191"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20101\u20104939\u20104014\u20101_16"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c06937"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1126953"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2019.100009"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004490050663"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042\u20106822(75)90284\u20106"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503203102"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505577102"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.7b00304"},{"key":"e_1_2_10_33_1","unstructured":"Kristopeit A. Konietzko J. Ma W. Phillips K. Swartz A. Wang S. C. Wenger M. D. Woodling M. &Matos T.Scalable chromatography process for purification of human cytomegalovirus(International Patent No. WO 2019\/209632 A1)."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.5731\/pdajpst.2013.00910"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2015.11.005"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2005.08.013"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102017\u20100176"},{"key":"e_1_2_10_38_1","unstructured":"U.S. Pharmacopea Monograph <1132>Residual Host Cell Protein Measurement in Biopharmaceuticals. Second supplement to USP38\u2010NF33.2016. European Pharmacopoeia Monograph 2.6.34. Host\u2010cell protein assays (04\/2017:20634)."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092443"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2016.02.011"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2021.462314"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.memsci.2017.11.022"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.260100612"},{"key":"e_1_2_10_44_1","unstructured":"U.S. Food and Drug Administration. (2004 September).Sterile drug products produced by aseptic processing \u2013 Current good manufacturing practice.U.S. Food and Drug Administration.https:\/\/www.fda.gov\/media\/71026\/download"},{"key":"e_1_2_10_45_1","unstructured":"The European Agency for the Evaluation of Medicinal Products. (1996 April).Note for guidance on manufacture of finished dosage form.Committee for Proprietary Medicinal Products (CPMP).https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guidline\/note\u2010guidance\u2010manufacture\u2010finished\u2010dosage\u2010form\u2010first\u2010version_en.pdf"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.27554"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.memsci.2021.119436"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/CPCY.77"}],"container-title":["Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/biot.202300041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:15:42Z","timestamp":1759940142000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/biot.202300041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/biot.202300041"],"URL":"https:\/\/doi.org\/10.1002\/biot.202300041","archive":["Portico"],"relation":{},"ISSN":["1860-6768","1860-7314"],"issn-type":[{"value":"1860-6768","type":"print"},{"value":"1860-7314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"article-number":"2300041"}}